Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia

TOKYO and STAMFORD, Conn.– March 12, 2019– Eisai Co., Ltd. (CEO: Haruo Naito,“Eisai”) and Imbrium Therapeutics L.P. (Imbrium Therapeutics), a clinical-stage biopharmaceutical company and operating subsidiary of Purdue...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news